Is Metformin + Vildagliptin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 6 valid registrations of Metformin + Vildagliptin, including GALVUS MET (850,50 mg,mg, Film-coated tablet, SAR 100.40); GALVUS MET (1000,50 mg,mg, Film-coated tablet, SAR 100.40); JALRA M (850,50 mg,mg, Film-coated tablet, SAR 93.70); JALRA M (1000,50 mg,mg, Film-coated tablet, SAR 98.70); Vtreat Met (50,850 mg,mg, Film-coated tablet, SAR 80.35).

Is Metformin + Vildagliptin authorised in the European Union?

EMA lists 4 centrally authorised medicines containing Metformin + Vildagliptin: Eucreas, Zomarist, Icandra (previously Vildagliptin / metformin hydrochloride Novartis), Vildagliptin / Metformin hydrochloride Accord.

Active substances

Metformin + Vildagliptin

SFDA 8
EMA 4
NHS prices 2

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
GALVUS MET	850,50 mg,mg	Film-coated tablet · Oral use	60 Blister	SAR 100.40	NCE · Prescription	NOVARTIS	Valid
GALVUS MET	1000,50 mg,mg	Film-coated tablet · Oral use	60 Blister	SAR 100.40	NCE · Prescription	NOVARTIS	Valid
JALRA M	850,50 mg,mg	Film-coated tablet · Oral use	60 Blister	SAR 93.70	Generic · Prescription	SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO	Valid
JALRA M	1000,50 mg,mg	Film-coated tablet · Oral use	60 Blister	SAR 98.70	Generic · Prescription	SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO	Valid
Vtreat Met	50,850 mg,mg	Film-coated tablet · Oral use	60 Blister	SAR 80.35	Generic · Prescription	Spectro Pharma	Valid
Vtreat Met	50,1000 mg,mg	Film-coated tablet · Oral use	60 Blister	SAR 84.60	Generic · Prescription	Spectro Pharma	Valid
Sensityn	1000,50 mg,mg	Film-coated tablet · Oral use	60 Blister	SAR 91.65	Generic · Prescription	ALPHA PHARMA INDUSTRY	Suspended · Not Marketed
Sensityn	850,50 mg,mg	Film-coated tablet · Oral use	60 Blister	SAR 87.05	Generic · Prescription	ALPHA PHARMA INDUSTRY	Suspended · Not Marketed

Indications — CHI Daman Drug Formulary

DIABETES MELLITUS TYPE 2

EMA European Union — centrally authorised medicines

Eucreas Novartis Europharm Limited · Authorised · authorised 14 Nov 2007 · ATC A10BD08

Therapeutic indication (EMA)

Eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

Zomarist Novartis Europharm Limited · Authorised · authorised 30 Nov 2008 · ATC A10BD08

Therapeutic indication (EMA)

Zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Novartis Europharm Limited · Authorised · authorised 30 Nov 2008 · ATC A10BD08

Therapeutic indication (EMA)

Icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

Vildagliptin / Metformin hydrochloride Accord Accord Healthcare S.L.U. · Authorised · authorised 24 Mar 2022 · ATC A10BD08

Therapeutic indication (EMA)

Vildagliptin/Metformin hydrochloride Accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
NHS Drug Tariff	Vildagliptin 50mg / Metformin 1g tablets	£19.09	60 tablet	1 Oct 2026
NHS Drug Tariff	Vildagliptin 50mg / Metformin 850mg tablets	£35.68	60 tablet	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.